Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)

Summary

Antimicrobial prophylaxis in urological procedures is aimed to reduce the risk of local and systemic postoperative infections such as urinary tract infection or surgical site infection. It should be recommended only when the potential benefit exceeds the anticipated risks and costs. However, a wide variation in the use of periprocedural prophylactic antibiotics has been demonstrated, which frequently is incurred as an inappropriate selection of antimicrobials, inadequate schedule of administration or excessive duration of prophylaxis. The increase in multidrug resistance of antibiotics in recent decades has been associated with its misuse, resulting in an increased rate of morbidity and mortality, prolonged hospital stays and increased care costs. Specifically, resistance to fluoroquinolones has increased its prevalence, a group of antibiotics widely used in urology. Therefore, local resistance patterns should be considered before following recommendations, especially in populations with poor control of antimicrobial use. Transurethral resection of bladder (TURB) has become a frequent surgical procedure, as it is the main diagnostic and therapeutic tool for bladder cancer, representing the ninth most common malignancy in the world. However, no recent randomized clinical trial has investigated antimicrobial prophylaxis for TURB. It is well known that an expected complication of TURB is urinary tract infection (UTI), which is the most common healthcare related infection worldwide. Under this premise, a randomized clinical trial is proposed to analyze the current panorama of UTI as a transcendent postoperative complication of TURB, under the context of the new emerging resistance parameters. The use of fosfomycin trometamol is proposed as a good potential option for urological procedures due to its high activity against multidrug-resistant gram-negative bacteria and its favorable pharmacokinetic parameters that guarantees wide tissue penetration and a high urinary concentration, in a single dose, the which will be compared with the control group with traditional prophylaxis (amikacin). The relative risk of UTI will be estimated, as well as the attributable risk of the main risk factors associated with this infection, allowing a better characterization of this population for adequate decision making regarding this clinical challenge.

Timeline

Start

2020-01-01

Primary completion

2023-04-01

Completion

2023-04-01

Publications

• Background Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol. 2007 Oct;178(4 Pt 1):1201-5; discussion 1205. doi: 10.1016/j.juro.2007.05.148. Epub 2007 Aug 14.
• Background Holzbeierlein JM, Smith JA Jr. Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS). Urol Clin North Am. 2000 Feb;27(1):15-24, vii-viii. doi: 10.1016/s0094-0143(05)70230-5.
• Background Mayorga, G; Ibarra, O; Sedano, B; Trujillo, O; Cornejo, D; Palmeros, R;…Pacheco, G. (2014) Aplicación de nomogramas en México para cáncer de vejiga en pacientes del Hospital General "Dr Manuel Gea González". Revista Mexicana de Urología, 74(1),3-8. https://doi.org/10.1016/s2007-4085(15)30002-1
• Background Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20. doi: 10.1080/03008880802285032.
• Background Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
• Background Sedano-Basilio, J; Mayorga-Gómez, E; Garza-Sainz, G; Conrejo-Dávila, V; Uberetagoyena-Tello de Meneses, I; Palmeros-Rodríguez, A;… Pacheco-Gahbler, C. (2016) Epidemiología de los tumores genitourinarios en una década. Revista Mexicana de Urología, 76(3), 131-140. https://doi.org/10.1016/j.uromx.2016.01.004
• Background Pycha, A. & Palermo, S. (2005) Transurethral Resection of Bladder Tumors. In R. Hoenfellner & J. Stolzenburg (Eds.) Manual Endourology (pp. 55-70) Berlín: Springer
• Background Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010 Mar 1;50(5):625-63. doi: 10.1086/650482.
• Background Junuzovic D, Hasanbegovic M, Zvizdic S, Hamzic S, Zunic L. The connection between endourological procedures and occurrence of urinary infections. Mater Sociomed. 2014 Aug;26(4):237-41. doi: 10.5455/msm.2014.237-241. Epub 2014 Aug 26.
• Background Alsaywid BS, Smith GH. Antibiotic prophylaxis for transurethral urological surgeries: Systematic review. Urol Ann. 2013 Apr;5(2):61-74. doi: 10.4103/0974-7796.109993.
• Background Matulewicz RS, Sharma V, McGuire BB, Oberlin DT, Perry KT, Nadler RB. The effect of surgical duration of transurethral resection of bladder tumors on postoperative complications: An analysis of ACS NSQIP data. Urol Oncol. 2015 Aug;33(8):338.e19-24. doi: 10.1016/j.urolonc.2015.05.011. Epub 2015 Jun 10.
• Background Rolston K.V. (2003) Pseudomonas Aeruginosa Infections in Cancer Patients. In: Hauser A.R., Rello J. (eds) Severe Infections Caused by Pseudomonas Aeruginosa. Perspectives on Critical Care Infectious Diseases, vol 7. Springer, Boston, MA
• Background Mazzei T, Diacciati S. Pharmacological aspects of the antibiotics used for urological diagnostic procedures. J Chemother. 2014 Oct;26 Suppl 1:S24-34. doi: 10.1179/1120009X14Z.000000000234.
• Background Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ; Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008 Apr;179(4):1379-90. doi: 10.1016/j.juro.2008.01.068. Epub 2008 Feb 20.
• Background Yamamoto S, Shigemura K, Kiyota H, Wada K, Hayami H, Yasuda M, Takahashi S, Ishikawa K, Hamasuna R, Arakawa S, Matsumoto T; Japanese Research Group for UTI. Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition. Int J Urol. 2016 Oct;23(10):814-824. doi: 10.1111/iju.13161. Epub 2016 Aug 16.
• Background Mrkobrada M, Ying I, Mokrycke S, Dresser G, Elsayed S, Bathini V, Boyce E, Luke P. CUA Guidelines on antibiotic prophylaxis for urologic procedures. Can Urol Assoc J. 2015 Jan-Feb;9(1-2):13-22. doi: 10.5489/cuaj.2382. No abstract available.
• Background Yokoyama M, Fujii Y, Yoshida S, Saito K, Koga F, Masuda H, Kobayashi T, Kawakami S, Kihara K. Discarding antimicrobial prophylaxis for transurethral resection of bladder tumor: a feasibility study. Int J Urol. 2009 Jan;16(1):61-3. doi: 10.1111/j.1442-2042.2008.02188.x.
• Background Sotomayor-de Zavaleta, M; Ponce de León-Garduño, A; Guzmán-Esquivel, J. & Rosas-Nava, E. (2015). Recomendaciones de expertos mexicanos en en tratamiento de las infecciones del tracto urinario en pacientes adultos, embarazadas y niños. Revista Mexicana de Urología, 72 (2), 1-46
• Background Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011.
• Background Panach-Navarrete J, Valls-Gonzalez L, Sanchez-Cano E, Medina-Gonzalez M, Castello-Porcar A, Martinez-Jabaloyas JM. Comparison of three different antibiotic protocols in transurethral resection of bladder tumour and the possible infectious risk factors: A non-randomized, prospective study. Can Urol Assoc J. 2018 Nov;12(11):E466-E674. doi: 10.5489/cuaj.5207. Epub 2018 Jun 8.
• Background Junuzovic, D; Hasanbegovic, M. & Kovacevic-Prstojevic, J (2011) The Incidence of Acquired Urinary Tract Infections in patients After Transurethral Resection of Bladder Tumors. MSM, 23 (2): 91-92
• Background Herwaldt LA, Cullen JJ, Scholz D, French P, Zimmerman MB, Pfaller MA, Wenzel RP, Perl TM. A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections. Infect Control Hosp Epidemiol. 2006 Dec;27(12):1291-8. doi: 10.1086/509827. Epub 2006 Nov 17.
• Background Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S113-9. doi: 10.1086/428051.
• Background Delavierre D, Huiban B, Fournier G, Le Gall G, Tande D, Mangin P. [The value of antibiotic prophylaxis in transurethral resection of bladder tumors. Apropos of 61 cases]. Prog Urol. 1993 Aug-Sep;3(4):577-82. French.
• Background Upton JD, Das S. Prophylactic antibiotics in transurethral resection of bladder tumors: are they necessary? Urology. 1986 May;27(5):421-3. doi: 10.1016/0090-4295(86)90406-1.
• Background MacDermott JP, Ewing RE, Somerville JF, Gray BK. Cephradine prophylaxis in transurethral procedures for carcinoma of the bladder. Br J Urol. 1988 Aug;62(2):136-9. doi: 10.1111/j.1464-410x.1988.tb04292.x.
• Background Ishizaka K, Kobayashi S, Machida T, Yoshida K. Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery. J Infect Chemother. 2007 Oct;13(5):324-31. doi: 10.1007/s10156-007-0544-5. Epub 2007 Oct 30.
• Background Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997 Apr;53(4):637-56. doi: 10.2165/00003495-199753040-00007.

Drugs

Indications